Back to Journals » OncoTargets and Therapy » Volume 6
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer
Authors Maric G, Rose A, Annis MG, Siegel PM
Received 7 March 2013
Accepted for publication 7 May 2013
Published 9 July 2013 Volume 2013:6 Pages 839—852
DOI https://doi.org/10.2147/OTT.S44906
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Gordana Maric,1,2 April AN Rose,3 Matthew G Annis,1,2 Peter M Siegel1,2,4,5
1Goodman Cancer Research Centre, 2Department of Medicine, 3Faculty of Medicine, 4Department of Biochemistry, 5Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada
Abstract: Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets against which such agents can be developed. The identification of tumor-associated antigens and the generation of antibody drug-conjugates represent an emerging area of intense interest and growth in the field of cancer therapeutics. Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies.
Keywords: GPNMB, osteoactivin, breast cancer, antibody-drug conjugates, CDX-011
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.